Redefine PET/CT imaging with the precision-driven performance of Biograph Vision™1. With industry-leading technical specifications, Biograph Vision delivers next-level image quality that transforms accurate decision-making.2,3
- Home
- Imagerie Médicale
- Molecular Imaging
- PET/CT Scanners
- Biograph Vision
Biograph Vision
Precision-driven performance
Fonctionnalités et avantages
Redefined technical precision
Biograph Vision’s groundbreaking technological performance redefines the limits of imaging. Featuring 3.2-mm lutetium oxyorthosilicate (LSO) crystals that are 100% covered by SiPMs2, Biograph Vision’s Optiso Ultra Dynamic Range (UDR) detector technology delivers high 48-mm3 volumetric resolution2 and 214-ps "true" time-of-flight performance.3 Biograph Vision leverages the full potential of SiPM technology to reveal the bigger picture for accurate and confident decision-making.
Unlocked imaging versatility
Unlock more clinical and research capabilities with Biograph Vision’s state-of-the-art detectability. Biograph Vision provides high image resolution and sensitivity for precise quantification that can positively impact health outcomes. UDR provides outstanding performance for a wide spectrum of count rates, enabling a broad variety of radiotracers at optimal doses.
Empowered operational performance
Biograph Vision empowers users to reduce scan time and injected dose to boost productivity, avoid unnecessary exposure, and increase patient comfort with the market’s highest effective sensitivity3 at 100 cps/kBq. Enhance patient and user experience with intelligent imaging capabilities that drive greater throughput while providing more consistent and accurate results. No matter the user, the patient,5 or the procedure, Biograph Vision delivers exceptional outcomes.
AIDAN Platform
Our intelligent imaging platform for Biograph™ PET/CT scanners that supports the demanding processing power of AI-based solutions.
Click plus (+) to find out our features
Exclusive bed design and wide bore
3.2-mm LSO crystals
Optiso UDR detector
CT capability
SAFIRE
Whole-body dynamic imaging
QualityGuard™FlowMotion AI™ FAST PET Workflow AIMultiparametric PET Suite AIOncoFreeze™ / OncoFreeze AIExclusive bed design and wide bore
Zero differential deflection for accurate attenuation correction and TG-66 compliant along with a 78-cm bore to support bariatric imaging and easier positioning of radiation oncology devices.
Our customers say...
"…by improving the spatial resolution…you have less partial volume effect, so you get sharper images and more accurate quantification."4
Ronald Boellaard, PhD
University Medical Center Groningen, Groningen, The Netherlands
"We have now already, as compared to the older system, reduced the activity we inject… Now it's probably 30% faster with about 30% less dose which is something very acceptable."4
John O. Prior, PhD, MD FEBNM
Professor and Head of Department of Nuclear Medicine and Molecular Imaging Lausanne, Switzerland
"Being more quantitative, our reproducibility can be that much better, and it may matter when we’re trying to do a repeat scan early on in a therapy and decide what to do."4
Richard E. Carson, PhD
Yale PET Center Yale School of Medicine, New Haven, CT, USA
Watch our videos showing Biograph Vision become a reality
Making vision a reality
Watch the full-length documentary video on how Biograph Vision became a reality. (9:16)
The passion behind the technology
Listen to first hand accounts from the talented men and women that worked on bringing Biograph Vision to reality. (5:49)
Biograph Vision - Features
Learn more about how Biograph Vision goes beyond digital. (1:31)
Approche clinique
1/25
Case 1
02Case 2
04Case 3
04Case 4
04Case 5
02Case 6
03Case 7
03Case 8
03
Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.
Case 8
Delineation of multiple skeletal, lymph node, liver, and soft tissue metastases with 18F FDG* PET/CT
Multiple hypermetabolic metastases in the liver, mediastinal lymph nodes, vertebrae, and soft tissue sharply delineated in 18F FDG PET/CT study on Biograph Vision reconstructed with high resolution at 440 x 440 matrix.
Examination protocol
Biograph Vision, 8.2 mCi (305 MBq) 18F FDG, 1 hour 41 minutes post-injection delay. CT: 100 kV, 11 eff mAs. 32 x 1.2 mm collimation, PET: 7 beds 3 minutes/bed 440 x 440 matrix.
Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.
Case 1
Normal brain metabolism in a subject with suspected multi-system atrophy
Normal brain study with sharp delineation of functioning cortex and increased contrast between cortex and white matter.
Clinical detail
A 67-year-old male with progressive muscular stiffness, difficulty in swallowing, and autonomic dysfunctions with no response to levodopa therapy; undergoing evaluation for striatal multi-system atrophy. A Fludeoxyglucose F 18 Injection.* (18F FDG) PET/CT scan of the brain was performed on Biograph Vision. The study shows normal uptake in brain with excellent delineation of functioning cortex and sharp contrast between cortex and white matter. Additionally there is sharp basal ganglial edge definition, especially the sharp margins and distinct separation of the head of caudate nucleus and putamen.
Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.
Case 1
Normal brain metabolism in a subject with suspected multi-system atrophy
Normal brain study with sharp delineation of functioning cortex and increased contrast between cortex and white matter.
Examination protocol
Biograph Vision, 5.4 mCi (200 MBq)18F FDG, 51 minutes post-injection delay. CT: 80 kV, 30 eff mAs. 128 x 0.6 mm collimation, PET: 15 minutes total scan time 440 x 440 matrix.
Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.
Case 2
Visualization of vascular blood pool during whole-body dynamic PET/CT acquisition
Fluoro-dihydrotestosterone (18F FDHT) PET/CT study in a patient with prostate cancer with biochemical relapse. Sequential whole-body dynamic FlowMotion™ acquisitions shortly after[a] 18 FDHT administration demonstrates blood pool activity within heart and major vessels as well as tracer clearance through liver, kidneys, and intestine.
Clinical detail
A 73-year-old male with prostate cancer treated with brachytherapy presented with biochemical relapse. The patient underwent PET/CT study following injection of androgen receptor imaging agent 18F –dihydrotestosterone (18F-FDHT) in order to assess presence of androgen receptor positive recurrence. PET/CT was performed on Biograph Vision. Images showed tracer within cardiac and vascular blood pool as well as in the liver. Significant clearance of tracer through the biliary tract and gall bladder, kidneys, and intestines is visualized. No well defined focal uptake suggestive of androgen receptor-avid metastatic lesions is visualized, although primary prostate bed showed significant uptake on higher intensity images. Sharp delineation of vascular structures, especially cavernous and sigmoid sinuses as well as carotid and subclavian vessels reflect the high overall image quality and low noise level in the Biograph Vision images.
Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.
Case 2
Visualization of vascular blood pool during whole-body dynamic PET/CT acquisition
Fluoro-dihydrotestosterone (18F FDHT) PET/CT study in a patient with prostate cancer with biochemical relapse. Sequential whole-body dynamic FlowMotion™ acquisitions shortly after[a] 18 FDHT administration demonstrates blood pool activity within heart and major vessels as well as tracer clearance through liver, kidneys, and intestine.
Examination protocol
Biograph Vision, 5.4 mCi (200 MBq)18F FDG, 51 minutes post-injection delay. CT: 80 kV, 30 eff mAs. 128 x 0.6 mm collimation, PET: 15 minutes total scan time 440 x 440 matrix.
[a] The tracer used in this case is a research radiopharmaceutical. It is neither recognized to be safe and effective by the FDA nor commercially available in the United States or in all countries worldwide. Siemens Healthineers does not make any claims regarding its use.
Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.
Case 2
Visualization of vascular blood pool during whole-body dynamic PET/CT acquisition
Fluoro-dihydrotestosterone (18F FDHT) PET/CT study in a patient with prostate cancer with biochemical relapse. Sequential whole-body dynamic FlowMotion™ acquisitions shortly after[a] 18 FDHT administration demonstrates blood pool activity within heart and major vessels as well as tracer clearance through liver, kidneys, and intestine.
Examination protocol
Biograph Vision, 5.4 mCi (200 MBq)18F FDG, 51 minutes post-injection delay. CT: 80 kV, 30 eff mAs. 128 x 0.6 mm collimation, PET: 15 minutes total scan time 440 x 440 matrix.
[a] The tracer used in this case is a research radiopharmaceutical. It is neither recognized to be safe and effective by the FDA nor commercially available in the United States or in all countries worldwide. Siemens Healthineers does not make any claims regarding its use.
Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.
Case 2
Visualization of vascular blood pool during whole-body dynamic PET/CT acquisition
Fluoro-dihydrotestosterone (18F FDHT) PET/CT study in a patient with prostate cancer with biochemical relapse. Sequential whole-body dynamic FlowMotion™ acquisitions shortly after[a] 18 FDHT administration demonstrates blood pool activity within heart and major vessels as well as tracer clearance through liver, kidneys, and intestine.
Examination protocol
Biograph Vision, 5.4 mCi (200 MBq)18F FDG, 51 minutes post-injection delay. CT: 80 kV, 30 eff mAs. 128 x 0.6 mm collimation, PET: 15 minutes total scan time 440 x 440 matrix.
[a] The tracer used in this case is a research radiopharmaceutical. It is neither recognized to be safe and effective by the FDA nor commercially available in the United States or in all countries worldwide. Siemens does not make any claims regarding its use.
Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.
Case 3
Visualization of 7 mm lymph node metastases on 68Ga-PSMA[a] evaluation of primary prostate cancer
68Ga-PSMA PET/CT in a patient with primary prostate cancer shows PSMA-avid primary tumor along with small PSMA-avid right external iliac lymph node metastases. Uptake in the kidneys, salivary gland, liver, intestine, and urinary bladder are within physiological limits.
Clinical detail
A 78-year-old male with primary prostate cancer underwent 68Ga-PSMA PET/CT initial staging. PET/CT was performed on Biograph Vision. The images showed high tracer uptake in kidneys, salivary glands, and bladder, which are at physiologically normal levels. The liver, spleen, and intestines also show lower but normal levels of uptake as well. There is also focal hypermetabolism in the prostate reflecting primary tumor and the small hypermetabolic right external iliac lymph node is suggestive of solitary nodal metastases. No other PSMA-avid metastatic lesions are visualized. Sharply delineated renal, salivary gland, bladder, and intestinal margins reflect the high overall image quality and low background noise level in the Biograph Vision images.
Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.
Case 3
Visualization of 7 mm lymph node metastases on 68Ga-PSMA[a] evaluation of primary prostate cancer
68Ga-PSMA PET/CT in a patient with primary prostate cancer shows PSMA-avid primary tumor along with small PSMA-avid right external iliac lymph node metastases. Uptake in the kidneys, salivary gland, liver, intestine, and urinary bladder are within physiological limits.
Examination protocol
Biograph Vision, 2.7 mCi (100 MBq) 68Ga-PSMA, 1 hour 45 minutes post-injection delay. CT: 100 kV, 16 eff mAs. 32 x 1.2 mm collimation, PET: 220 x 220 matrix.
[a] The tracer used in this case is a research radiopharmaceutical. It is neither recognized to be safe and effective by the FDA nor commercially available in the United States or in all countries worldwide. Siemens does not make any claims regarding its use.
Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.
Case 3
Visualization of 7 mm lymph node metastases on 68Ga-PSMA[a] evaluation of primary prostate cancer
Visualization of 7 mm lymph node metastases on 68Ga-PSMA[a] evaluation of primary prostate cancer
68Ga-PSMA PET/CT in a patient with primary prostate cancer shows PSMA-avid primary tumor along with small PSMA-avid right external iliac lymph node metastases. Uptake in the kidneys, salivary gland, liver, intestine, and urinary bladder are within physiological limits.
Examination protocol
Biograph Vision, 2.7 mCi (100 MBq) 68Ga-PSMA, 1 hour 45 minutes post-injection delay. CT: 100 kV, 16 eff mAs. 32 x 1.2 mm collimation, PET: 220 x 220 matrix.
[a] The tracer used in this case is a research radiopharmaceutical. It is neither recognized to be safe and effective by the FDA nor commercially available in the United States or in all countries worldwide. Siemens does not make any claims regarding its use.
Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.
Case 3
Visualization of 7 mm lymph node metastases on 68Ga-PSMA[a] evaluation of primary prostate cancer
Visualization of 7-mm lymph node metastases on 68Ga-PSMA[a] evaluation of primary prostate cancer
68Ga-PSMA PET/CT in a patient with primary prostate cancer shows PSMA-avid primary tumor along with small PSMA-avid right external iliac lymph node metastases. Uptake in the kidneys, salivary gland, liver, intestine, and urinary bladder are within physiological limits.
Examination protocol
Biograph Vision, 2.7 mCi (100 MBq) 68Ga-PSMA, 1 hour 45 minutes post-injection delay. CT: 100 kV, 16 eff mAs. 32 x 1.2 mm collimation, PET: 220 x 220 matrix.
[a] The tracer used in this case is a research radiopharmaceutical. It is neither recognized to be safe and effective by the FDA nor commercially available in the United States or in all countries worldwide. Siemens does not make any claims regarding its use.
Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.
Case 4
High contrast in pelvic nodal and hepatic metastases in a patient with operated ovarian carcinoma seen by 18F FDG* PET/CT
Hypermetabolic right obturator and liver metastases visualized with high contrast on 18F FDG PET/CT in a patient with operated ovarian carcinoma.
Clinical detail
A 49-year-old woman with a history of operated ovarian carcinoma with suspected recurrence underwent 18F FDG PET/CT for restaging. A PET/CT was performed on Biograph Vision. The images showed hypermetabolic metastases in the right obturator node, anterior pelvic wall above, and adjacent to the bladder as well as multiple small liver metastases in the posterior aspect of the right lobe (Segment VII) and in the caudate lobe. Sharp delineation of small liver lesions with high contrast compared to normal liver without respiratory gating reflect the overall high image quality and high lesion contrast to background in the Biograph Vision images.
Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.
Case 4
High contrast in pelvic nodal and hepatic metastases in a patient with operated ovarian carcinoma seen by 18F FDG* PET/CT
Hypermetabolic right obturator and liver metastases visualized with high contrast on 18F FDG PET/CT in a patient with operated ovarian carcinoma.
Examination protocol
Biograph Vision, 7.5 mCi (280 MBq) 18 FDG, 1 hour 49 minutes post-injection delay. CT: 140 kV, 16 eff mAs. 32 x 1.2 mm collimation, PET: 7 beds 3 minutes/bed 220 x 220 matrix.
Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.
Case 4
High contrast in pelvic nodal and hepatic metastases in a patient with operated ovarian carcinoma seen by 18F FDG* PET/CT
Hypermetabolic right obturator and liver metastases visualized with high contrast on 18F FDG PET/CT in a patient with operated ovarian carcinoma.
Examination protocol
Biograph Vision, 7.5 mCi (280 MBq) 18 FDG, 1 hour 49 minutes post-injection delay. CT: 140 kV, 16 eff mAs. 32 x 1.2 mm collimation, PET: 7 beds 3 minutes/bed 220 x 220 matrix.
Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.
Case 4
High contrast in pelvic nodal and hepatic metastases in a patient with operated ovarian carcinoma seen by 18F FDG* PET/CT
Hypermetabolic right obturator and liver metastases visualized with high contrast on 18F FDG PET/CT in a patient with operated ovarian carcinoma.
Examination protocol
Biograph Vision, 7.5 mCi (280 MBq) 18 FDG, 1 hour 49 minutes post-injection delay. CT: 140 kV, 16 eff mAs. 32 x 1.2 mm collimation, PET: 7 beds 3 minutes/bed 220 x 220 matrix.
Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.
Case 5
Small liver metastases in a patient with operated colorectal carcinoma detected with 18F FDG* PET/CT
Small hypermetabolic foci in the right lobe of liver close to the diaphragm visualized with high contrast and minimal motion related blurring with 18F FDG PET/CT.
Clinical detail
A 69-year-old male with a history of operated colorectal carcinoma with suspected recurrence underwent 18F FDG PET/CT for restaging. A PET/CT was performed on Biograph Vision. The images showed sharp delineation of small hypermetabolic metastasis in the right lobe of liver near the dome of diaphragm (Segment VII). Intense uptake in the abdominal wall is suggestive of metastatic deposit. Mildly increased uptake in mediastinal lymph nodes are possibly secondary to inflammation. High contrast of small liver metastases without significant motion related blurring even without respiratory gating reflects high overall image quality and increased lesion contrast to background in the Biograph Vision images.
Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.
Case 5
Small liver metastases in a patient with operated colorectal carcinoma detected with 18F FDG* PET/CT
Small hypermetabolic foci in the right lobe of liver close to the diaphragm visualized with high contrast and minimal motion related blurring with 18F FDG PET/CT.
Examination protocol
Biograph Vision, 7.3 mCi (270 MBq) 18F FDG, 1 hour 50 minutes post-injection delay. CT: 100 kV, 10 eff mAs. 32 x 1.2 mm collimation, PET: 7 beds 3 minutes/bed 440 x 440 matrix.
* Indications and Important Safety Information.
Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.
Case 6
18F-Fluroestradiol[a] PET/CT in a patient with breast carcinoma
Sharp visualization of physiological uptake in biliary tract, gall bladder, liver, and intestines in a patient with breast carcinoma without estrogen receptor positive metastases undergoing PET/CT imaging with 18F-Fluoroestradiol (FES).
Clinical detail
A 77-year-old female with a history of breast carcinoma treated with left mastectomy and chemo-radiotherapy presented with pain in the thoracic wall along with pleural effusion. The patient underwent 18F Fluoroestradiol (FES) PET/CT to assess presence of estrogen receptor (ER) positive metastases. A PET/CT was performed on Biograph Vision™. High resolution PET images show faint uptake in the left pleura suggestive of ER positive pleural thickening. The PET/CT images also sharply delineates physiological uptake in the gall bladder and biliary tract and intestine reflecting hepatobiliary clearance of tracer. Sharp definition of biliary tree with high contrast compared to background even at 440 x 440 matrix reconstructed resolution reflect the high overall image quality of Biograph Vision images.
Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.
Case 6
18F-Fluroestradiol[a] PET/CT in a patient with breast carcinoma
Sharp visualization of physiological uptake in biliary tract, gall bladder, liver, and intestines in a patient with breast carcinoma without estrogen receptor positive metastases undergoing PET/CT imaging with 18F-Fluoroestradiol (FES).
Examination protocol
Biograph Vision, 5.2 mCi (195 MBq) 18F FES, 1 hour 29 minutes post-injection delay. CT: 100 kV, 13 eff mAs. 32 x 1.2 mm collimation, PET: 7 beds 3 minutes/bed 440 x 440 matrix.
[a] The tracer used in this case is a research radiopharmaceutical. It is neither recognized to be safe and effective by the FDA nor commercially available in the United States or in all countries worldwide. Siemens does not make any claims regarding its use.
Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.
Case 6
18F-Fluroestradiol[a] PET/CT in a patient with breast carcinoma
Sharp visualization of physiological uptake in biliary tract, gall bladder, liver, and intestines in a patient with breast carcinoma without estrogen receptor positive metastases undergoing PET/CT imaging with 18F-Fluoroestradiol (FES).
Examination protocol
Biograph Vision, 5.2 mCi (195 MBq) 18F FES, 1 hour 29 minutes post-injection delay. CT: 100 kV, 13 eff mAs. 32 x 1.2 mm collimation, PET: 7 beds 3 minutes/bed 440 x 440 matrix.
[a] The tracer used in this case is a research radiopharmaceutical. It is neither recognized to be safe and effective by the FDA nor commercially available in the United States or in all countries worldwide. Siemens does not make any claims regarding its use.
Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.
Case 7
Sharp delineation of physiological uptake in vascular walls, marrow, and intestine with 18F FDG* PET/CT
Physiological uptake in aortic walls, carotid and subclavian vessels as well as normal marrow uptake in the vertebrae, ribs and pelvis sharply delineated in 18F FDG PET/CT study on Biograph Vision™ reconstructed with high resolution at 440 x 440 matrix.
Clinical detail
A 79-year-old male with unknown clinical history. A PET/CT was performed on Biograph Vision. High resolution PET images show sharp delineation of physiological uptake in the aortic walls, atrial walls, carotid, and subclavian vessels. Normal marrow uptake within vertebrae, ribs, and pelvis are well visualized. Physiological uptake in the gastric mucosa and intestines, with note made of sharply delineated descending colon. Sharp delineation of normal structures like rib and vessels with low background uptake reflect high overall image quality even at 440x440 matrix reconstructed resolution of Biograph Vision images.
Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.
Case 7
Sharp delineation of physiological uptake in vascular walls, marrow, and intestine with 18F FDG* PET/CT
Physiological uptake in aortic walls, carotid and subclavian vessels as well as normal marrow uptake in the vertebrae, ribs and pelvis sharply delineated in 18F FDG PET/CT study on Biograph Vision™ reconstructed with high resolution at 440 x 440 matrix.
Examination protocol
Biograph Vision, 8.2 mCi (305 MBq) 18F FDG, 1 hour 41 minutes post-injection delay. CT: 100 kV, 11 eff mAs. 32 x 1.2 mm collimation, PET: 7 beds 3 minutes/bed 440 x 440 matrix.
Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.
Case 7
Sharp delineation of physiological uptake in vascular walls, marrow, and intestine with 18F FDG* PET/CT
Sharp delineation of physiological uptake in vascular walls, marrow, and intestine with 18F FDG* PET/CT
Physiological uptake in aortic walls, carotid and subclavian vessels as well as normal marrow uptake in the vertebrae, ribs and pelvis sharply delineated in 18F FDG PET/CT study on Biograph Vision™ reconstructed with high resolution at 440 x 440 matrix.
Examination protocol
Biograph Vision, 8.2 mCi (305 MBq) 18F FDG, 1 hour 41 minutes post-injection delay. CT: 100 kV, 11 eff mAs. 32 x 1.2 mm collimation, PET: 7 beds 3 minutes/bed 440 x 440 matrix.
Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.
Case 8
Delineation of multiple skeletal, lymph node, liver, and soft tissue metastases with 18F FDG* PET/CT
Multiple hypermetabolic metastases in the liver, mediastinal lymph nodes, vertebrae, and soft tissue sharply delineated in 18F FDG PET/CT study on Biograph Vision reconstructed with high resolution at 440 x 440 matrix.
Clinical detail
70-year-old male. Though clinical history unknown, there are obviously multiple metastases as shown on PET/CT performed on the Biograph Vision. High resolution PET images show multiple hypermetabolic metastases in the liver, mediastinal lymph nodes, vertebrae and soft tissue. Sharp delineation with high lesion contrast of small metastases in the vertebrae, pelvis, mediastinal nodes and soft tissue especially in the left thigh reflect the high image quality even at 440x440 matrix reconstructed resolution of the Biograph Vision images.
Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.
Case 8
Delineation of multiple skeletal, lymph node, liver, and soft tissue metastases with 18F FDG* PET/CT
Multiple hypermetabolic metastases in the liver, mediastinal lymph nodes, vertebrae, and soft tissue sharply delineated in 18F FDG PET/CT study on Biograph Vision reconstructed with high resolution at 440 x 440 matrix.
Examination protocol
Biograph Vision, 8.2 mCi (305 MBq) 18F FDG, 1 hour 41 minutes post-injection delay. CT: 100 kV, 11 eff mAs. 32 x 1.2 mm collimation, PET: 7 beds 3 minutes/bed 440 x 440 matrix.
Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.
Case 8
Delineation of multiple skeletal, lymph node, liver, and soft tissue metastases with 18F FDG* PET/CT
Multiple hypermetabolic metastases in the liver, mediastinal lymph nodes, vertebrae, and soft tissue sharply delineated in 18F FDG PET/CT study on Biograph Vision reconstructed with high resolution at 440 x 440 matrix.
Examination protocol
Biograph Vision, 8.2 mCi (305 MBq) 18F FDG, 1 hour 41 minutes post-injection delay. CT: 100 kV, 11 eff mAs. 32 x 1.2 mm collimation, PET: 7 beds 3 minutes/bed 440 x 440 matrix.
Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.
Case 1
Normal brain metabolism in a subject with suspected multi-system atrophy
Normal brain study with sharp delineation of functioning cortex and increased contrast between cortex and white matter.
Clinical detail
A 67-year-old male with progressive muscular stiffness, difficulty in swallowing, and autonomic dysfunctions with no response to levodopa therapy; undergoing evaluation for striatal multi-system atrophy. A Fludeoxyglucose F 18 Injection.* (18F FDG) PET/CT scan of the brain was performed on Biograph Vision. The study shows normal uptake in brain with excellent delineation of functioning cortex and sharp contrast between cortex and white matter. Additionally there is sharp basal ganglial edge definition, especially the sharp margins and distinct separation of the head of caudate nucleus and putamen.
Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.
Case 1
Normal brain metabolism in a subject with suspected multi-system atrophy
Normal brain study with sharp delineation of functioning cortex and increased contrast between cortex and white matter.
Examination protocol
Biograph Vision, 5.4 mCi (200 MBq)18F FDG, 51 minutes post-injection delay. CT: 80 kV, 30 eff mAs. 128 x 0.6 mm collimation, PET: 15 minutes total scan time 440 x 440 matrix.
Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.
Case 2
Visualization of vascular blood pool during whole-body dynamic PET/CT acquisition
Fluoro-dihydrotestosterone (18F FDHT) PET/CT study in a patient with prostate cancer with biochemical relapse. Sequential whole-body dynamic FlowMotion™ acquisitions shortly after[a] 18 FDHT administration demonstrates blood pool activity within heart and major vessels as well as tracer clearance through liver, kidneys, and intestine.
Clinical detail
A 73-year-old male with prostate cancer treated with brachytherapy presented with biochemical relapse. The patient underwent PET/CT study following injection of androgen receptor imaging agent 18F –dihydrotestosterone (18F-FDHT) in order to assess presence of androgen receptor positive recurrence. PET/CT was performed on Biograph Vision. Images showed tracer within cardiac and vascular blood pool as well as in the liver. Significant clearance of tracer through the biliary tract and gall bladder, kidneys, and intestines is visualized. No well defined focal uptake suggestive of androgen receptor-avid metastatic lesions is visualized, although primary prostate bed showed significant uptake on higher intensity images. Sharp delineation of vascular structures, especially cavernous and sigmoid sinuses as well as carotid and subclavian vessels reflect the high overall image quality and low noise level in the Biograph Vision images.
Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.
Case 2
Visualization of vascular blood pool during whole-body dynamic PET/CT acquisition
Fluoro-dihydrotestosterone (18F FDHT) PET/CT study in a patient with prostate cancer with biochemical relapse. Sequential whole-body dynamic FlowMotion™ acquisitions shortly after[a] 18 FDHT administration demonstrates blood pool activity within heart and major vessels as well as tracer clearance through liver, kidneys, and intestine.
Examination protocol
Biograph Vision, 5.4 mCi (200 MBq)18F FDG, 51 minutes post-injection delay. CT: 80 kV, 30 eff mAs. 128 x 0.6 mm collimation, PET: 15 minutes total scan time 440 x 440 matrix.
[a] The tracer used in this case is a research radiopharmaceutical. It is neither recognized to be safe and effective by the FDA nor commercially available in the United States or in all countries worldwide. Siemens Healthineers does not make any claims regarding its use.
Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.
Case 2
Visualization of vascular blood pool during whole-body dynamic PET/CT acquisition
Fluoro-dihydrotestosterone (18F FDHT) PET/CT study in a patient with prostate cancer with biochemical relapse. Sequential whole-body dynamic FlowMotion™ acquisitions shortly after[a] 18 FDHT administration demonstrates blood pool activity within heart and major vessels as well as tracer clearance through liver, kidneys, and intestine.
Examination protocol
Biograph Vision, 5.4 mCi (200 MBq)18F FDG, 51 minutes post-injection delay. CT: 80 kV, 30 eff mAs. 128 x 0.6 mm collimation, PET: 15 minutes total scan time 440 x 440 matrix.
[a] The tracer used in this case is a research radiopharmaceutical. It is neither recognized to be safe and effective by the FDA nor commercially available in the United States or in all countries worldwide. Siemens Healthineers does not make any claims regarding its use.
Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.
Case 2
Visualization of vascular blood pool during whole-body dynamic PET/CT acquisition
Fluoro-dihydrotestosterone (18F FDHT) PET/CT study in a patient with prostate cancer with biochemical relapse. Sequential whole-body dynamic FlowMotion™ acquisitions shortly after[a] 18 FDHT administration demonstrates blood pool activity within heart and major vessels as well as tracer clearance through liver, kidneys, and intestine.
Examination protocol
Biograph Vision, 5.4 mCi (200 MBq)18F FDG, 51 minutes post-injection delay. CT: 80 kV, 30 eff mAs. 128 x 0.6 mm collimation, PET: 15 minutes total scan time 440 x 440 matrix.
[a] The tracer used in this case is a research radiopharmaceutical. It is neither recognized to be safe and effective by the FDA nor commercially available in the United States or in all countries worldwide. Siemens does not make any claims regarding its use.
Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.
Case 3
Visualization of 7 mm lymph node metastases on 68Ga-PSMA[a] evaluation of primary prostate cancer
68Ga-PSMA PET/CT in a patient with primary prostate cancer shows PSMA-avid primary tumor along with small PSMA-avid right external iliac lymph node metastases. Uptake in the kidneys, salivary gland, liver, intestine, and urinary bladder are within physiological limits.
Clinical detail
A 78-year-old male with primary prostate cancer underwent 68Ga-PSMA PET/CT initial staging. PET/CT was performed on Biograph Vision. The images showed high tracer uptake in kidneys, salivary glands, and bladder, which are at physiologically normal levels. The liver, spleen, and intestines also show lower but normal levels of uptake as well. There is also focal hypermetabolism in the prostate reflecting primary tumor and the small hypermetabolic right external iliac lymph node is suggestive of solitary nodal metastases. No other PSMA-avid metastatic lesions are visualized. Sharply delineated renal, salivary gland, bladder, and intestinal margins reflect the high overall image quality and low background noise level in the Biograph Vision images.
Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.
Case 3
Visualization of 7 mm lymph node metastases on 68Ga-PSMA[a] evaluation of primary prostate cancer
68Ga-PSMA PET/CT in a patient with primary prostate cancer shows PSMA-avid primary tumor along with small PSMA-avid right external iliac lymph node metastases. Uptake in the kidneys, salivary gland, liver, intestine, and urinary bladder are within physiological limits.
Examination protocol
Biograph Vision, 2.7 mCi (100 MBq) 68Ga-PSMA, 1 hour 45 minutes post-injection delay. CT: 100 kV, 16 eff mAs. 32 x 1.2 mm collimation, PET: 220 x 220 matrix.
[a] The tracer used in this case is a research radiopharmaceutical. It is neither recognized to be safe and effective by the FDA nor commercially available in the United States or in all countries worldwide. Siemens does not make any claims regarding its use.
Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.
Case 3
Visualization of 7 mm lymph node metastases on 68Ga-PSMA[a] evaluation of primary prostate cancer
Visualization of 7 mm lymph node metastases on 68Ga-PSMA[a] evaluation of primary prostate cancer
68Ga-PSMA PET/CT in a patient with primary prostate cancer shows PSMA-avid primary tumor along with small PSMA-avid right external iliac lymph node metastases. Uptake in the kidneys, salivary gland, liver, intestine, and urinary bladder are within physiological limits.
Examination protocol
Biograph Vision, 2.7 mCi (100 MBq) 68Ga-PSMA, 1 hour 45 minutes post-injection delay. CT: 100 kV, 16 eff mAs. 32 x 1.2 mm collimation, PET: 220 x 220 matrix.
[a] The tracer used in this case is a research radiopharmaceutical. It is neither recognized to be safe and effective by the FDA nor commercially available in the United States or in all countries worldwide. Siemens does not make any claims regarding its use.
Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.
Case 3
Visualization of 7 mm lymph node metastases on 68Ga-PSMA[a] evaluation of primary prostate cancer
Visualization of 7-mm lymph node metastases on 68Ga-PSMA[a] evaluation of primary prostate cancer
68Ga-PSMA PET/CT in a patient with primary prostate cancer shows PSMA-avid primary tumor along with small PSMA-avid right external iliac lymph node metastases. Uptake in the kidneys, salivary gland, liver, intestine, and urinary bladder are within physiological limits.
Examination protocol
Biograph Vision, 2.7 mCi (100 MBq) 68Ga-PSMA, 1 hour 45 minutes post-injection delay. CT: 100 kV, 16 eff mAs. 32 x 1.2 mm collimation, PET: 220 x 220 matrix.
[a] The tracer used in this case is a research radiopharmaceutical. It is neither recognized to be safe and effective by the FDA nor commercially available in the United States or in all countries worldwide. Siemens does not make any claims regarding its use.
Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.
Case 4
High contrast in pelvic nodal and hepatic metastases in a patient with operated ovarian carcinoma seen by 18F FDG* PET/CT
Hypermetabolic right obturator and liver metastases visualized with high contrast on 18F FDG PET/CT in a patient with operated ovarian carcinoma.
Clinical detail
A 49-year-old woman with a history of operated ovarian carcinoma with suspected recurrence underwent 18F FDG PET/CT for restaging. A PET/CT was performed on Biograph Vision. The images showed hypermetabolic metastases in the right obturator node, anterior pelvic wall above, and adjacent to the bladder as well as multiple small liver metastases in the posterior aspect of the right lobe (Segment VII) and in the caudate lobe. Sharp delineation of small liver lesions with high contrast compared to normal liver without respiratory gating reflect the overall high image quality and high lesion contrast to background in the Biograph Vision images.
Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.
Case 4
High contrast in pelvic nodal and hepatic metastases in a patient with operated ovarian carcinoma seen by 18F FDG* PET/CT
Hypermetabolic right obturator and liver metastases visualized with high contrast on 18F FDG PET/CT in a patient with operated ovarian carcinoma.
Examination protocol
Biograph Vision, 7.5 mCi (280 MBq) 18 FDG, 1 hour 49 minutes post-injection delay. CT: 140 kV, 16 eff mAs. 32 x 1.2 mm collimation, PET: 7 beds 3 minutes/bed 220 x 220 matrix.
Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.
Case 4
High contrast in pelvic nodal and hepatic metastases in a patient with operated ovarian carcinoma seen by 18F FDG* PET/CT
Hypermetabolic right obturator and liver metastases visualized with high contrast on 18F FDG PET/CT in a patient with operated ovarian carcinoma.
Examination protocol
Biograph Vision, 7.5 mCi (280 MBq) 18 FDG, 1 hour 49 minutes post-injection delay. CT: 140 kV, 16 eff mAs. 32 x 1.2 mm collimation, PET: 7 beds 3 minutes/bed 220 x 220 matrix.
Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.
Case 4
High contrast in pelvic nodal and hepatic metastases in a patient with operated ovarian carcinoma seen by 18F FDG* PET/CT
Hypermetabolic right obturator and liver metastases visualized with high contrast on 18F FDG PET/CT in a patient with operated ovarian carcinoma.
Examination protocol
Biograph Vision, 7.5 mCi (280 MBq) 18 FDG, 1 hour 49 minutes post-injection delay. CT: 140 kV, 16 eff mAs. 32 x 1.2 mm collimation, PET: 7 beds 3 minutes/bed 220 x 220 matrix.
Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.
Case 5
Small liver metastases in a patient with operated colorectal carcinoma detected with 18F FDG* PET/CT
Small hypermetabolic foci in the right lobe of liver close to the diaphragm visualized with high contrast and minimal motion related blurring with 18F FDG PET/CT.
Clinical detail
A 69-year-old male with a history of operated colorectal carcinoma with suspected recurrence underwent 18F FDG PET/CT for restaging. A PET/CT was performed on Biograph Vision. The images showed sharp delineation of small hypermetabolic metastasis in the right lobe of liver near the dome of diaphragm (Segment VII). Intense uptake in the abdominal wall is suggestive of metastatic deposit. Mildly increased uptake in mediastinal lymph nodes are possibly secondary to inflammation. High contrast of small liver metastases without significant motion related blurring even without respiratory gating reflects high overall image quality and increased lesion contrast to background in the Biograph Vision images.
Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.
Case 5
Small liver metastases in a patient with operated colorectal carcinoma detected with 18F FDG* PET/CT
Small hypermetabolic foci in the right lobe of liver close to the diaphragm visualized with high contrast and minimal motion related blurring with 18F FDG PET/CT.
Examination protocol
Biograph Vision, 7.3 mCi (270 MBq) 18F FDG, 1 hour 50 minutes post-injection delay. CT: 100 kV, 10 eff mAs. 32 x 1.2 mm collimation, PET: 7 beds 3 minutes/bed 440 x 440 matrix.
* Indications and Important Safety Information.
Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.
Case 6
18F-Fluroestradiol[a] PET/CT in a patient with breast carcinoma
Sharp visualization of physiological uptake in biliary tract, gall bladder, liver, and intestines in a patient with breast carcinoma without estrogen receptor positive metastases undergoing PET/CT imaging with 18F-Fluoroestradiol (FES).
Clinical detail
A 77-year-old female with a history of breast carcinoma treated with left mastectomy and chemo-radiotherapy presented with pain in the thoracic wall along with pleural effusion. The patient underwent 18F Fluoroestradiol (FES) PET/CT to assess presence of estrogen receptor (ER) positive metastases. A PET/CT was performed on Biograph Vision™. High resolution PET images show faint uptake in the left pleura suggestive of ER positive pleural thickening. The PET/CT images also sharply delineates physiological uptake in the gall bladder and biliary tract and intestine reflecting hepatobiliary clearance of tracer. Sharp definition of biliary tree with high contrast compared to background even at 440 x 440 matrix reconstructed resolution reflect the high overall image quality of Biograph Vision images.
Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.
Case 6
18F-Fluroestradiol[a] PET/CT in a patient with breast carcinoma
Sharp visualization of physiological uptake in biliary tract, gall bladder, liver, and intestines in a patient with breast carcinoma without estrogen receptor positive metastases undergoing PET/CT imaging with 18F-Fluoroestradiol (FES).
Examination protocol
Biograph Vision, 5.2 mCi (195 MBq) 18F FES, 1 hour 29 minutes post-injection delay. CT: 100 kV, 13 eff mAs. 32 x 1.2 mm collimation, PET: 7 beds 3 minutes/bed 440 x 440 matrix.
[a] The tracer used in this case is a research radiopharmaceutical. It is neither recognized to be safe and effective by the FDA nor commercially available in the United States or in all countries worldwide. Siemens does not make any claims regarding its use.
Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.
Case 6
18F-Fluroestradiol[a] PET/CT in a patient with breast carcinoma
Sharp visualization of physiological uptake in biliary tract, gall bladder, liver, and intestines in a patient with breast carcinoma without estrogen receptor positive metastases undergoing PET/CT imaging with 18F-Fluoroestradiol (FES).
Examination protocol
Biograph Vision, 5.2 mCi (195 MBq) 18F FES, 1 hour 29 minutes post-injection delay. CT: 100 kV, 13 eff mAs. 32 x 1.2 mm collimation, PET: 7 beds 3 minutes/bed 440 x 440 matrix.
[a] The tracer used in this case is a research radiopharmaceutical. It is neither recognized to be safe and effective by the FDA nor commercially available in the United States or in all countries worldwide. Siemens does not make any claims regarding its use.
Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.
Case 7
Sharp delineation of physiological uptake in vascular walls, marrow, and intestine with 18F FDG* PET/CT
Physiological uptake in aortic walls, carotid and subclavian vessels as well as normal marrow uptake in the vertebrae, ribs and pelvis sharply delineated in 18F FDG PET/CT study on Biograph Vision™ reconstructed with high resolution at 440 x 440 matrix.
Clinical detail
A 79-year-old male with unknown clinical history. A PET/CT was performed on Biograph Vision. High resolution PET images show sharp delineation of physiological uptake in the aortic walls, atrial walls, carotid, and subclavian vessels. Normal marrow uptake within vertebrae, ribs, and pelvis are well visualized. Physiological uptake in the gastric mucosa and intestines, with note made of sharply delineated descending colon. Sharp delineation of normal structures like rib and vessels with low background uptake reflect high overall image quality even at 440x440 matrix reconstructed resolution of Biograph Vision images.
Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.
Case 7
Sharp delineation of physiological uptake in vascular walls, marrow, and intestine with 18F FDG* PET/CT
Physiological uptake in aortic walls, carotid and subclavian vessels as well as normal marrow uptake in the vertebrae, ribs and pelvis sharply delineated in 18F FDG PET/CT study on Biograph Vision™ reconstructed with high resolution at 440 x 440 matrix.
Examination protocol
Biograph Vision, 8.2 mCi (305 MBq) 18F FDG, 1 hour 41 minutes post-injection delay. CT: 100 kV, 11 eff mAs. 32 x 1.2 mm collimation, PET: 7 beds 3 minutes/bed 440 x 440 matrix.
Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.
Case 7
Sharp delineation of physiological uptake in vascular walls, marrow, and intestine with 18F FDG* PET/CT
Sharp delineation of physiological uptake in vascular walls, marrow, and intestine with 18F FDG* PET/CT
Physiological uptake in aortic walls, carotid and subclavian vessels as well as normal marrow uptake in the vertebrae, ribs and pelvis sharply delineated in 18F FDG PET/CT study on Biograph Vision™ reconstructed with high resolution at 440 x 440 matrix.
Examination protocol
Biograph Vision, 8.2 mCi (305 MBq) 18F FDG, 1 hour 41 minutes post-injection delay. CT: 100 kV, 11 eff mAs. 32 x 1.2 mm collimation, PET: 7 beds 3 minutes/bed 440 x 440 matrix.
Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.
Case 8
Delineation of multiple skeletal, lymph node, liver, and soft tissue metastases with 18F FDG* PET/CT
Multiple hypermetabolic metastases in the liver, mediastinal lymph nodes, vertebrae, and soft tissue sharply delineated in 18F FDG PET/CT study on Biograph Vision reconstructed with high resolution at 440 x 440 matrix.
Clinical detail
70-year-old male. Though clinical history unknown, there are obviously multiple metastases as shown on PET/CT performed on the Biograph Vision. High resolution PET images show multiple hypermetabolic metastases in the liver, mediastinal lymph nodes, vertebrae and soft tissue. Sharp delineation with high lesion contrast of small metastases in the vertebrae, pelvis, mediastinal nodes and soft tissue especially in the left thigh reflect the high image quality even at 440x440 matrix reconstructed resolution of the Biograph Vision images.
Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.
Case 8
Delineation of multiple skeletal, lymph node, liver, and soft tissue metastases with 18F FDG* PET/CT
Multiple hypermetabolic metastases in the liver, mediastinal lymph nodes, vertebrae, and soft tissue sharply delineated in 18F FDG PET/CT study on Biograph Vision reconstructed with high resolution at 440 x 440 matrix.
Examination protocol
Biograph Vision, 8.2 mCi (305 MBq) 18F FDG, 1 hour 41 minutes post-injection delay. CT: 100 kV, 11 eff mAs. 32 x 1.2 mm collimation, PET: 7 beds 3 minutes/bed 440 x 440 matrix.
Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.
Case 8
Delineation of multiple skeletal, lymph node, liver, and soft tissue metastases with 18F FDG* PET/CT
Multiple hypermetabolic metastases in the liver, mediastinal lymph nodes, vertebrae, and soft tissue sharply delineated in 18F FDG PET/CT study on Biograph Vision reconstructed with high resolution at 440 x 440 matrix.
Examination protocol
Biograph Vision, 8.2 mCi (305 MBq) 18F FDG, 1 hour 41 minutes post-injection delay. CT: 100 kV, 11 eff mAs. 32 x 1.2 mm collimation, PET: 7 beds 3 minutes/bed 440 x 440 matrix.
1/25
* Indications and Important Safety Information.
Caractéristiques techniques
Transcend digital with the Optiso UDR detector
Optiso UDR’s proprietary 3.2-mm LSO crystals move silicon photomultiplier (SiPM) technology beyond digital to a new level of precision to help you detect small lesions, devise accurate treatment strategies\, and achieve optimal performance in a wide range of count rates.
Take a look inside Biograph Vision
See how the Optiso UDR PET detector advances PET/CT beyond digital.
Spécifications techniques
Gantry | |
Bore diameter | 78 cm |
Tunnel length | 136 cm |
Table capacity | 227 kg (500 lb) |
CT | |
Generator power | 80 kW (100 kW optional) |
Rotation times | 0.33, 0.305, 0.285 s |
Tube voltages | 70, 80, 100, 120, 140 kV |
Iterative reconstruction | SAFIRE5 |
Metal artifact reduction | iMAR5 |
Slices | 64, 128 |
PET | |
Axial field of view | 26.3 cm |
Crystal size | 3.2 x 3.2 x 20 mm |
SiPM coverage of crystal array | 100% |
Effective sensitivity | 100 cps/kBq |
Effective peak NEC rate | 1,789 kcps ≤ 30 kBq/cc |
Time of flight performance | 214 ps |
Testimonial
Watch expert views on Biograph Vision
Accuracy to reveal the bigger picture
See smaller lesions, with better contrast. Hear what the experts say about the accuracy of Biograph Vision. (0:50)
Performance to maximize efficiency
Market-leading time of flight and sensitivity2,6 mean lower patient exposure and reduced tracer cost.3 Learn what the performance of Biograph Vision can do for your patients. (1:07)
Reproducibility to understand disease progression better
Absolute quantification and improved resolution and effective sensitivity3 enable you to evaluate treatment effectiveness earlier. Listen to the experts tell us how this affects their practice. (1:32)
Learn more about Biograph Vision
Avez-vous jugé cette information utile?
Merci beaucoup
Voulez-vous faire un retour détaillé ?
125 / 125
1
Biograph Vision is not commercially available in all countries. Its future availability cannot be guaranteed. Please contact your local Siemens Healthineers organization for further details.
2
Based on internal measurements available at time of publication. Data on file.
3
Compared to current state-of-the-art technologies. Data on file.
4
The statements by Siemens Healthineers customers described herein are based on results that were achieved in the customer’s unique setting. Because there is no “typical” hospital or laboratory and many variables exist (eg, hospital size, samples mix, case mix, level of IT, and/or automation adoption) there can be no guarantee that other customers will achieve the same results.
5
Based on patient weight limit of 227 kg (500 lb).
6
Based on competitive literature available at time of publication. Data on file.